CareDx, Inc.
1 Tower Pl, 9th Floor
South San Francisco, CA 94080
United States
328 articles about CareDx, Inc.
-
CareDx Partners with the European Society for Organ Transplantation to Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals
3/30/2022
CareDx, Inc. today announced that it is partnering with the European Society for Organ Transplantation (ESOT) to provide education for its membership on the clinical evidence supporting the use of donor-derived cell-free DNA.
-
UPDATE -- CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
3/23/2022
CareDx, Inc. today announced that the Company won its false advertising case against Natera.
-
CareDx Announces XenoSure and XenoMap
3/23/2022
CareDx, Inc. announced the availability of XenoSure™ donor-derived cell-free DNA and XenoMap™ gene-expression profiling for investigational use in xenotransplantation research and post-xenotransplant clinical monitoring.
-
CareDx Brings Together Leading Transplant Experts to Share Latest Advancements in the Field of Xenotransplantation
3/16/2022
CareDx, Inc. announced that it will hold a virtual “Xenotransplantation Innovation Day” featuring a leading panel of transplant experts who will share the latest advancements in xenotransplantation after genetically modified pig kidneys and, separately, a pig heart were recently successfully transplanted, two medical firsts.
-
CareDx Announces Cibiltech Initiates CIBIL Study Using iBox Artificial Intelligence to Monitor Kidney Transplant Patients
3/3/2022
CareDx, Inc. announced that its strategic partner, Cibiltech, a French MedTech company that develops artificial intelligence-based products for predictive medicine, has initiated the CIBIL clinical trial to evaluate the performance of iBox artificial intelligence as a prognostic measure of organ survival in kidney transplant patients.
-
CareDx Reports Fourth Quarter and Full Year 2021 Results
2/24/2022
CareDx, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021.
-
CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring World’s First Successful Living Xenotransplantation
2/22/2022
CareDx, Inc. today announced that its non-invasive organ transplant surveillance solutions are being used to help monitor post-operative graft health in the world’s first successful heart xenotransplantation.
-
CareDx Taps into Its Patient Network to Deliver Insights on Transplant Needs
2/8/2022
CareDx, Inc. announced that it has submitted insights from over 250 kidney, heart, lung, and liver transplant patients to the Centers for Medicare and Medicaid Services in response to their Request for Information on the “Health and Safety Requirements for Transplant Programs, Organ Procurement Organizations, and End-Stage Renal Disease Facilities.”.
-
CareDx Joins Forces with MOTTEP to Host “Heart Health” Webinar for Transplant Patients
2/7/2022
CareDx, Inc. is hosting a webinar focused on educating kidney transplant on how to maintain optimal heart health to help prevent cardiovascular complications, which can contribute to kidney transplant failure.
-
CareDx To Participate In Upcoming Conferences - Feb 03, 2022
2/3/2022
CareDx, Inc. announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the Raymond James 43rd Annual Institutional Investors Conference.
-
CareDx Joins Forces with MOTTEP to Increase Organ Donations for Minority Transplant Patients and Support High-Risk, Underserved Communities
1/20/2022
CareDx, Inc. announced its partnership with MOTTEP to help advance its mission of increasing the number of minority-donated organs and greater adoption of disease prevention behaviors which reduce the incidence of end-stage disease and the need for organ transplantation in high-risk, underserved communities.
-
CareDx Partners with Multiple Biotechnology Companies to Use AlloCell in CAR T-Cell Therapy Clinical Studies
1/11/2022
CareDx, Inc. today announced recent drug development collaborations with three leading cell therapy biopharmaceutical companies to use CareDx's AlloCell™ surveillance in the respective companies' ongoing CAR T-cell therapy clinical studies.
-
NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection
1/7/2022
CareDx, Inc. today announced the results of a study led by the National Institutes of Health.
-
CareDx Partners with ISHLT in a Transplant Innovation Research Grant to Improve Outcomes for Heart and Lung Transplant Patients
1/4/2022
CareDx, Inc. today announced a partnership with the International Society for Heart and Lung Transplantation (ISHLT) in offering an Innovation Challenge Award to clinicians to further AlloSure® and AlloMap® research.
-
CareDx Enrolls First Patient in LungCare Registry Study to Measure Impact of Multimodality Assessment on Lung Transplant Patient Outcomes
12/16/2021
CareDx, Inc. today announced the enrollment of the first patient in the multicenter, observational, prospective ALAMO registry to improve lung transplant patient care.
-
CareDx Partners with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Organization in Launching Prospective, Multi-Center Pediatric Kidney Transplant Study
12/13/2021
CareDx, Inc. today announced a partnership with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) organization to use their patient registry to evaluate the long-term impact of using AlloSure ® Kidney, for routine organ transplant surveillance in pediatric kidney patients.
-
CareDx Named One of the Fastest-Growing Companies in North America on the Deloitte Technology Fast 500™ for the Third Consecutive Year
11/19/2021
CareDx, Inc. today announced its inclusion on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.
-
CareDx Enrolls First Patients in the Largest Digital Study in Transplant Using AlloCare to Assess Patient Outcomes
11/18/2021
CareDx, Inc. (Nasdaq: CDNA) – today announced the enrollment of the first patients in what will be the largest ever digital study measuring the impact of AlloCare™, a tech-enabled mobile health app, on organ transplant patient outcomes.
-
CareDx To Participate in Upcoming Conferences - Nov 15, 2021
11/15/2021
CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the Company will participate in the 12th Annual Jefferies London Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference.
-
CareDx Focuses on Innovation in Transplant at ASN Kidney Week Two AlloSure abstracts will be featured at ASN
11/3/2021
CareDx, Inc. today announced key data and presentations at the American Society of Nephrology (ASN) Kidney Week 2021, which will be held virtually from November 4-7, 2021.